{"slideshow_credits": null, "snippet": "Women who can benefit from the drug need to be aware of the risks and how to mitigate them.", "abstract": "Editorial offers conditional praise for FDA's approval of drug Addyi to treat sexual dysfunction in women; questions, however, whether decision was unduly influenced by manufacturer Sprout Pharmaceuticals, which took part in campaign focusing on gender-bias as possible reason no libido-enhancing drug has ever been approved for women; cautions women and their doctors to talk frankly and work together to mitigate drug's potential risks. ", "section_name": "Opinion", "print_page": "26", "document_type": "article", "byline": {"person": [], "original": "By THE EDITORIAL BOARD", "organization": "THE EDITORIAL BOARD"}, "web_url": "http://www.nytimes.com/2015/08/21/opinion/little-pink-pill-for-women-comes-with-risks.html", "lead_paragraph": "Women who can benefit from the drug need to be aware of the risks and how to mitigate them.", "headline": {"print_headline": "A Libido Pill and Its Side Effects  ", "main": "\u2018Little Pink Pill\u2019 for Women Comes With Risks", "content_kicker": "Editorial", "kicker": "Editorial"}, "_id": "55d6d16338f0d81d6b2effbb", "word_count": "455", "multimedia": [{"height": 126, "url": "images/2015/08/21/opinion/21fri3web/21fri3web-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/08/21/opinion/21fri3web/21fri3web-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 350, "url": "images/2015/08/21/opinion/21fri3web/21fri3web-articleLarge.jpg", "legacy": {"xlarge": "images/2015/08/21/opinion/21fri3web/21fri3web-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "350"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/08/21/opinion/21fri3web/21fri3web-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/08/21/opinion/21fri3web/21fri3web-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-08-21T00:00:00Z", "source": "The New York Times", "news_desk": "Editorial", "keywords": [{"name": "subject", "value": "Editorials", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Addyi (Drug)", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Food and Drug Administration", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Sex", "is_major": "Y", "rank": "4"}, {"name": "subject", "value": "Women and Girls", "is_major": "Y", "rank": "5"}, {"name": "organizations", "value": "Sprout Pharmaceuticals Inc", "is_major": "Y", "rank": "6"}, {"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "N", "rank": "7"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "8"}], "blog": [], "subsection_name": null, "type_of_material": "Editorial"}